Skip to main content
Journal cover image

Reduced expression of hMSH2 and hMLH1 and risk of prostate cancer: a case-control study.

Publication ,  Journal Article
Strom, SS; Spitz, MR; Yamamura, Y; Babaian, RJ; Scardino, PT; Wei, Q
Published in: Prostate
June 1, 2001

BACKGROUND: Although prostate cancer is the most common incident cancer in men, not much is known about its etiology. We tested the hypothesis that expression levels of hMSH2 and hMLH1 in unaffected (normal) tissue play a role in the etiology of prostate cancer. METHODS: Total RNA was extracted from peripheral blood lymphocytes of subjects ascertained by a case-control study (70 patients and 97 age- and ethnicity-matched controls). A multiplex reverse transcription-polymerase chain reaction assay was used to simultaneously evaluate the relative expression of hMSH2 and hMLH1, using beta-actin as the internal control. RESULTS: The relative gene expression levels of hMSH2 and hMLH1 were significantly lower in cases than in controls (P < 0.05 for both genes). When compared with the highest tertile of the controls, low expression levels (the middle and lowest tertiles) of hMLH1 were associated with significantly increased risk of prostate cancer in a dose-response relationship (ORs = 2.68, and 4.31; 95% confidence interval = 1.00-7.23 and 1.64-11.30, respectively) after adjustment for age, ethnicity, smoking status, and family history of prostate cancer. CONCLUSIONS: These results suggest that reduced expression of hMLH1 in peripheral lymphocytes may be a risk factor for prostate cancer. However, it cannot be ruled out that the reduced expression we observed may be caused by the disease status. Our findings and the factors that may affect the expression of hMLH1 need further confirmation in larger prospective studies.

Duke Scholars

Published In

Prostate

DOI

ISSN

0270-4137

Publication Date

June 1, 2001

Volume

47

Issue

4

Start / End Page

269 / 275

Location

United States

Related Subject Headings

  • Testosterone
  • Statistics, Nonparametric
  • Reverse Transcriptase Polymerase Chain Reaction
  • Proto-Oncogene Proteins
  • Prostatic Neoplasms
  • Pilot Projects
  • Oncology & Carcinogenesis
  • Nuclear Proteins
  • Neoplasm Proteins
  • MutS Homolog 2 Protein
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Strom, S. S., Spitz, M. R., Yamamura, Y., Babaian, R. J., Scardino, P. T., & Wei, Q. (2001). Reduced expression of hMSH2 and hMLH1 and risk of prostate cancer: a case-control study. Prostate, 47(4), 269–275. https://doi.org/10.1002/pros.1071
Strom, S. S., M. R. Spitz, Y. Yamamura, R. J. Babaian, P. T. Scardino, and Q. Wei. “Reduced expression of hMSH2 and hMLH1 and risk of prostate cancer: a case-control study.Prostate 47, no. 4 (June 1, 2001): 269–75. https://doi.org/10.1002/pros.1071.
Strom SS, Spitz MR, Yamamura Y, Babaian RJ, Scardino PT, Wei Q. Reduced expression of hMSH2 and hMLH1 and risk of prostate cancer: a case-control study. Prostate. 2001 Jun 1;47(4):269–75.
Strom, S. S., et al. “Reduced expression of hMSH2 and hMLH1 and risk of prostate cancer: a case-control study.Prostate, vol. 47, no. 4, June 2001, pp. 269–75. Pubmed, doi:10.1002/pros.1071.
Strom SS, Spitz MR, Yamamura Y, Babaian RJ, Scardino PT, Wei Q. Reduced expression of hMSH2 and hMLH1 and risk of prostate cancer: a case-control study. Prostate. 2001 Jun 1;47(4):269–275.
Journal cover image

Published In

Prostate

DOI

ISSN

0270-4137

Publication Date

June 1, 2001

Volume

47

Issue

4

Start / End Page

269 / 275

Location

United States

Related Subject Headings

  • Testosterone
  • Statistics, Nonparametric
  • Reverse Transcriptase Polymerase Chain Reaction
  • Proto-Oncogene Proteins
  • Prostatic Neoplasms
  • Pilot Projects
  • Oncology & Carcinogenesis
  • Nuclear Proteins
  • Neoplasm Proteins
  • MutS Homolog 2 Protein